Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling by unknown
RESEARCH Open Access
Let-7a-transfected mesenchymal stem cells
ameliorate monocrotaline-induced
pulmonary hypertension by suppressing
pulmonary artery smooth muscle cell
growth through STAT3-BMPR2 signaling
Gesheng Cheng1, Xingye Wang1*, Yongxin Li2 and Lu He1
Abstract
Background: Cell-based gene therapy has become a subject of interest for the treatment of pulmonary arterial
hypertension (PAH), a devastating disease characterized by pulmonary artery smooth muscle cell (PASMC)
hyperplasia. Mesenchymal stem cells (MSCs) have been recently acknowledged as a potential cell vector for
gene therapy. Here, we investigated the effect of MSC-based let-7a for PAH.
Methods: After isolation and identification of MSCs from rat bone marrow, cells were infected with recombinant
adenovirus vector Ad-let-7a. Lewis rats were subcutaneously injected with monocrotaline (MCT) to induce PAH,
followed by the administration of MSCs, MSCs-NC (miR-control), or MSC-let-7a, respectively. Then, right ventricular
systolic pressure (RVSP), right ventricular hypertrophy, and pulmonary vascular remodeling were evaluated. Rat
pulmonary artery smooth muscle cells (rPASMCs) under hypoxia were co-cultured with MSCs or MSC-let-7a. Cell
proliferation and apoptosis were separately determined by 3H thymidine incorporation and flow cytometry analysis.
The underlying mechanism was also investigated.
Results: MSC transplantation enhanced let-7a levels in MCT-induced PAH rats. After injection with MSC-let-7a,
RVSP, right ventricular hypertrophy, and pulmonary vascular remodeling were notably ameliorated, indicating a
protective effect of MSC-let-7a against PAH. When co-cultured with MSC-let-7a, hypoxia-triggered PASMC proliferation
was obviously attenuated, concomitant with the decrease in cell proliferation-associated proteins. Simultaneously, the
resistance of PASMCs to apoptosis was remarkably abrogated by MSC-let-7a administration. A mechanism assay
revealed that MSC-let-7a restrained the activation of signal transducers and activators of transcription 3 (STAT3)
and increased its downstream bone morphogenetic protein receptor 2 (BMPR2) expression. Importantly, preconditioning
with BMPR2 siRNA dramatically abated the suppressive effects of MSC-let-7a on PASMC proliferation and apoptosis
resistance.
Conclusions: Collectively, this study suggests that MSCs modified with let-7a may ameliorate the progression of PAH
by inhibiting PASMC growth through the STAT3-BMPR2 signaling, supporting a promising therapeutic strategy for
PAH patients.
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Background
Pulmonary arterial hypertension (PAH) is a well-
recognized, devastating, and life-threatening disease. As
a common progressive disease, it is characterized by a
sustained increase in pulmonary arterial pressure, right
heart dysfunction, and vascular remodeling, leading to
the high morbidity and mortality of patients with lung
and heart diseases [1–3]. Despite therapeutic advances
in PAH treatment, the 3-year survival rate is still less than
60% [4]. Therefore, an understanding of the molecular
mechanism underlying PAH development is urgently
required for improving the therapeutic strategies.
Recently, cell-based gene therapies have garnered in-
creasing interest due to their beneficial roles in ameli-
orating the progression of PAH [5–7]. Mesenchymal
stem cells (MSCs) are the preferred cell model for cell-
based therapy because of their high expansion in culture,
reproducible potential, and capacity to differentiate into
various lineages. They can be mobilized and migrate into
injury sites to orchestrate the repair response [8]. Applica-
tion of naïve MSCs attenuates monocrotaline (MCT)-
induced PAH, indicating a beneficial effect of stem cell
therapy for PAH disorders [9, 10]. More interestingly,
administration of MSCs modified with prostacyclin syn-
thase or endothelial nitric oxide synthase not only
abrogated right ventricular (RV) hypertrophy and car-
diovascular remodeling, but also improved survival
time in PAH rats [5, 6]. Additionally, MSCs expressing
heme oxygenase-1 enhanced the protective effect of
MSCs on hypoxia-triggered PAH by attenuating lung
inflammation and smooth muscle cell proliferation,
suggesting a promising strategy against PAH based on
MSC-based gene therapy [11].
MicroRNAs (miRNAs) orchestrate various patho-
physiological processes including lipid metabolism, vas-
cular remodeling, and tissue repair [12–15]. Abnormal
expression of miRNAs has been corroborated in several
lung-related diseases, such as PAH [16]. The presence of
some miRNAs that are correlated with PAH severity can
retard the pathological progression of PAH, indicating a
potential innovative therapy for the treatment of PAH
[17]. Animals with PAH show a dramatic downregula-
tion of let-7a in the lungs [16]. An analogous decrease in
let-7a was also validated when cells were exposed to
chronic hypoxia, suggesting a potential role of let-7a in
the development of PAH [18]. Moreover, let-7 expres-
sion also negatively correlated with the severity of PAH
in patients with systemic scleroderma [19]. Unfortu-
nately, its function in PAH remains poorly defined. In
this study, we aimed to explore the function of MSCs
transfected with let-7a in PAH development. Further-
more, the effects of MSC-let-7a on pulmonary artery
smooth muscle cell (PASMC) growth, as well as the
underlying mechanism, were also explored.
Methods
Antibodies and reagents
The signal transducer and activator of transcription 3
(STAT3) inhibitor, S31-201, was acquired from Sigma
(St. Louis, MO, USA). The primary antibodies against
STAT3, phosphorylated STAT3-Tyr-705 (p-STAT3), pro-
liferating cell nuclear antigen (PCNA), and bone mor-
phogenetic protein receptor 2 (BMPR2) were purchased
from Abcam (Cambridge, UK). Rabbit antibodies against
rat p21 and α-smooth muscle actin (SMA) were obtained
from Sigma. Anti-rat antibodies of Ki67 and cyclin D1
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA).
Animals
For experiments using animals, 6-week-old male Lewis
rats were purchased from Beijing Vital River Laboratory
Animal Technology Co., Ltd. (Beijing, China). All animal
care and experimental procedures were undertaken with
approval from the Institutional Animal Care and Use
Committee of the First Affiliated Hospital of Xi’an Jiaotong
University (SCXK-2012-003). Rats were acclimatized for
1 week prior to the subsequent treatments.
Isolation and expansion of rat MSCs
Preparation of rat MSCs (rMSCs) was conducted fol-
lowing previously published methods [6]. Briefly, bone
marrow cells from Lewis rats were mechanically disso-
ciated by flushing the femur and tibia cavities under
sterile conditions. The isolated cells were then sus-
pended in α-MEM medium containing 10% fetal bovine
serum (FBS), 100 U/mL penicillin and 100 μg/mL
streptomycin on 75-cm2 tissue culture flasks. Three
days later, non-adherent cells were removed, and the
adherent cells that had grown to 90% confluence were
considered as passage (P)0 MSCs. For expansion, cells
were diluted in the ratio of 1:2 per passage and con-
tinuously cultured in rMSC medium. Passages 3–4
were used for the subsequent experiments.
Characterization of MSCs in vitro
The surface marker proteins of MSCs were identified by
incubation with fluorescein isothiocyanate (FITC)-conju-
gated monoclonal antibodies against CD34, CD45,
CD44, and CD90 (all from Abcam, Cambridge, MA,
USA). Then, the labeled cells were analyzed by a FACS-
can flow cytometer (Becton Dickinson, NJ, USA). To
evaluate osteogenic ability of MSCs, MSCs of P3 were
incubated with osteogenic medium for 4 weeks and sub-
sequently stained with 2% Alizarin Red S (Sigma). Cells
were stained with 0.3% Oil Red O (Sigma) to assess adi-
pogenic ability. All specimens were analyzed micro-
scopically (IX70, Olympus, Tokyo, Japan).
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Adenovirus production for let-7a in rMSCs
Adenoviral vectors of AdmiRa-rno-let-7a expressing
green fluorescent protein (GFP) and miR-control (nor-
mal control; NC) were obtained from Applied Biological
Materials Inc. (Richmond, BC, Canada). The above
adenovirus was packaged according to the protocol pro-
vided by the manufacturers. After amplification and
purification, virus titers were measured by the p24
ELISA kit (Cell Biolabs, Inc., San Diego, CA, USA).
Then, the obtained rMSCs at P3–P4 were infected with
the above adenovirus to generate the let-7a-overexpressed
MSCs. The infection efficiency was evaluated by GFP and
quantitative RT-PCR. Cell that overexpressed let-7a were
then harvested with phosphate-buffered saline (PBS)
buffer supplement with 0.25% trypsin and 1 mmol/L
EDTA before use.
PAH model
To construct the PAH model, Lewis rats received a sub-
cutaneous injection of monocrotaline (MCT; Sigma, St.
Louis, MO, USA; 60 mg/kg) as previously reported [6].
Rats injected with 0.9% saline were defined as the nega-
tive control.
Animal groups
About 3 weeks later, rats treated with MCT were ran-
domized to four groups (n = 10/group, n = 40 in total):
rats treated with PBS (MCT + PBS group); rats received
MSCs (MCT +MSC group); rats injected with MSC-let-
7a (MCT +MSC-let-7a group); rats received MSC-NC
(MCT +MSC-NC group). For cell implantation, ap-
proximately 3 × 106 cells in PBS were slowly injected
into rats via the tail vein. Rats without MCT administra-
tion were defined as the control group.
Collection of blood specimens
EDTA-anticoagulated whole blood samples were col-
lected at 7, 14, and 21 day after the injection of MSC-
let-7a, MSCs, or PBS. The bloods were centrifuged at
1000 g for 10 min. The obtained specimens were then
stored at –70 °C until analysis.
Hemodynamic evaluation and right ventricular
hypertrophy
Three weeks after MSC administration, rats were anes-
thetized with sodium pentobarbital (30 mg/kg) to per-
form the hemodynamic study. The 3-F Miller catheters
were inserted into the right ventricle through the right
jugular vein to assess the right ventricular systolic pres-
sure (RVSP). After euthanizing with an overdose of
pentobarbital, the lungs and hearts were collected. The
ratios of right ventricle weight to body weight (RVW/
BW) and right ventricle/left ventricle + septum weight
(RV/LV + Sep) were detected and defined as the indexes
of right ventricular hypertrophy [5, 6]. For vascular re-
modeling evaluation, lung tissues were embedded in par-
affin and then were cut into serial 4-μm thick sections.
After staining with hematoxylin and eosin, the wall
thickness (n = 5 measurements/rat in 10 rats) was calcu-
lated as follows: wall thickness (%) = (external diameter
– internal diameter)/ external diameter × 100 [7].
Cell culture
Rat pulmonary artery smooth muscle cells (rPASMCs)
were purchased from Pricells Company (Wuhan, China)
and cultured in DMEM medium containing 5% FBS, 100
U/ml penicillin, and 100 μg/ml streptomycin. Cells from
P5–P10 were used for the subsequent experiments. All
cells were maintained in 5% CO2 at 37 °C.
Knockdown of BMPR2 by siRNA
To knockdown BMPR2 expression in MSCs, three spe-
cific pairs of siRNA sequences were designed according
to rat BMPR2 mRNA (GenBank accession number:
NM_080407.1). Their sequences were as follows: siRNA-
BMPR2-1500 (sense, 5′-GGUUGGCACAAUCCGCUAU-
3′; antisense, 5′-AUAGCGGAUUGUGCCAACC-3′), siR
NA-BMPR2-1947 (sense, 5′-GCAGAACGAACGCAAC-
CUA-3′; antisense, 5′-UAGGUUGCGUUCGUUCUGC-
3′), and siRNA-BMPR2-2173 (sense, 5′-CCAGAAACAA
GCGUCACAA-3′; antisense, 5′- UUGUGACGCUUGU
UUCUGG-3′). The scramble siRNA (siRNA-NC) were
used as negative control, and the sequences were as
follow: forward 5′-GGUCACGCUAACGCGUUAU-3′,
reverse 5′-AUAACGCGUUAGCGUGACC-3′. For trans-
fection, cells were grown to approximately 50–60%
confluence. Then, cells were transfected with siRNAs at 4
nM using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer's directions.
Approximately 24 h later, the efficiency of BMPR2 siRNA
was analyzed by Western blotting.
Co-culture of MSCs and rPASMCs
MSCs and PASMCs were co-cultured using the transwell
system as previously described [20]. Briefly, rPASMCs were
exposed to hypoxia with 3% oxygen concentration or nor-
moxia for 24 h. Cells were then seeded in the transwell
insert membrane with 0.4-mm diameter pores. Then, the
modified MSCs (MSC-NC or MSC-let-7a) were cultured in
the lower chamber. Twenty-four hours later, the PASMCs
were collected for cell proliferation and apoptosis assay.
RNA extraction and quantitative RT-PCR
Total RNA from blood samples was obtained by the
RNAprep Pure Hi-Blood Kit (TIANGEN, Beijing, China)
according to the manufacturer’s directions. Total RNA
from lung tissues and cells was extracted using TRIzol
reagent (Invitrogen Life Technologies, Carlsbad, CA,
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USA). For mRNA detection, reverse transcription was
performed to synthesize the cDNA with RevertAidTM
First Strand cDNA Synthesis Kits (Fermentas, St. Leon-
Rot, Germany). Then, quantitative RT-PCR was carried
out to evaluate the mRNA levels of let-7a using SYBR
premix Ex Taq (TaKaRa) according to the manufacturer’s
protocol. The specific primers for let-7a, Ki67, cyclinD1,
PCNA, and fibronectin (Fn) were used as described pre-
viously [21–23]. The expression of let-7a was normalized
to U6, and β-actin was used as a quality control to
normalize other gene expression. All data were calcu-
lated with the 2–ΔΔCt equation.
Western blotting
The collected tissues and cells were lysed with RIPA lysis
buffer (Thermo scientific, Rockford, IL, USA) followed
by the detection of protein concentration using the BCA
assay kit (Pierce, Rockford, IL, USA). Then, equal
amounts of samples were subjected to 12% SDS–PAGE,
and the separated proteins were electro-blotted onto
PVDF membranes (Sigma), which were blocked with 5%
nonfat dry milk in TBST for 2 h. The membranes were
then incubated at room temperature with the primary
antibodies against Ki67, cyclin D1, p21, PCNA, and α-
SMA. The HRP-conjugated secondary antibodies were
then added for further incubation for 1 h. The binding
proteins were visualized using chemiluminescence (Santa
Cruz, CA, USA) and quantified by a Gel DocTM XR im-
aging system (Bio-Rad Laboratories, Hercules, CA, USA).
Cell proliferation assay
PASMC proliferation was assessed using 3H thymidine
(3H-TdR; Atomic Nucleus Research Institute, Shanghai,
China) incorporation in accordance with the manufac-
turer’s instructions. Briefly, 37 kBq/ml of 3H-TdR was
added to the co-culture system. Twenty-four hours later,
cell viability was analyzed by detecting radioactivity with
a liquid scintillation counter (Beckmen, USA). At least
three independent experiments were performed to
evaluate cell viability.
Flow cytometry analysis
Following co-incubation with MSCs for 24 h, the PASMCs
were collected. Then, cells were trypsinized and sus-
pended with binding buffer. About 10 μl Annexin V-FITC
and 5 μl PI were added for further incubation at room
temperature. Fifteen minutes later, all specimens were
subjected to a FACScan flow cytometer (Becton Dickin-
son, NJ) to analyze the relative apoptosis via at least three
independent repeats.
Caspase-3 activity
Caspase-3 activity was performed using the Caspase-Glo
3/7 Assay kit (Promega, Madison, WI, USA). Following
the co-culture with MSC-NC or MSC-let-7a, caspase-3
activity was detected according to the manufacturer’s
instructions. The results were obtained from three inde-
pendent experiments.
Statistical analysis
All experiments were conducted independently at least
three times and all results are shown as mean ± SD. The
unpaired Student’s t test was used to analyze the statis-
tical significance of differences between two groups.
Comparisons among three or more groups were made
with ANOVA followed by the post-hoc test, and p < 0.05
was considered statistically significant.
Results
Characterization of MSCs isolated from bone marrow
As shown in Fig. 1a, most MSCs at P3 were spindle-like
in shape and adhered to the plastic tissue culture dishes
after culture for 7 days. Moreover, flow cytometric assay
confirmed that MSCs were stained negatively for the
hematopoietic markers CD34 and CD45, but highly
expressed the mesenchymal associated markers CD44
and CD90 (Fig. 1b). To further evaluate the multipo-
tency of MSCs differentiating into osteogenic and adipo-
genic cells, MSCs were incubated in osteogenic and
adipogenic medium. As expected, MSCs could form
alizarin-red-positive mineral deposits (Fig. 1c). Further-
more, MSCs exhibited an adipogenic potential by detect-
ing lipid droplet deposition through Oil Red O staining
(Fig. 1d). Therefore, all data suggested that we success-
fully isolated MSCs with stemness.
Expression levels of let-7a in MSCs
Consistent with a previous report [16], an obvious at-
tenuation of let-7a expression was substantiated in PAH
rats (Fig. 2a). Engraftment of MSCs dramatically amelio-
rated the downregulation of let-7a expression in PAH
animals, indicating a potential critical role of let-7a in
the development of PAH. Furthermore, a higher expres-
sion of let-7a was also conferred in MSCs exposed to
hypoxia, in contrast to the normoxia group (Fig. 2b). To
investigate the effect of MSCs modified with let-7a on
PAH development, MSCs were infected with the recom-
binant Ad-let-7a or Ad-NC. Quantitative RT-PCR assay
showed that the expression of let-7a in let-7a+ MSCs was
obviously enhanced relative to the control group (Fig. 2c).
Transplantation of MSC-let-7a ameliorates MCT-triggered
right ventricular impairment
To explore the efficacy of MSC-based let-7a elevation in
reversing MCT-triggered PAH, the constructed MSC-
let-7a were injected into rats with MCT treatment. In
contrast to the PBS group, the expression of let-7a was
obviously increased at 7 days after injection with MSCs,
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which was further elevated in the MSC-let-7a group.
Moreover, 3 week later, the expression of let-7a was still
maintained at a relatively higher level in MSC-let-7a
groups relative to PBS and MSC groups (Fig. 3a). Fur-
thermore, the expression of let-7a in lung tissues was
also increased in MSC-let-7a groups (Fig. 3b). Addition-
ally, rats that received MCT treatment provoked a
strong RVSP, which was obviously attenuated by MSC
treatment (Fig. 3c). Interestingly, MSC-let-7a administra-
tion further reduced RVSP in contrast to MSC-treated
groups. Importantly, MSC-let-7a transplantation strik-
ingly antagonized the MCT-induced increase in the ratio
of RV/(LV + Sep), an index of right ventricular hyper-
trophy (RVH), relative to the MSC-treated groups, but
without a statistically significant difference between nor-
mal MSC and NC-MSC groups (Fig. 3d). Consistently,
the increase in the ratio of RV/BW induced by MCT,
another index of RVH, was also obviously decreased fol-
lowing MSC-let-7a treatment (Fig. 3e). These results
indicate a potential protective effect of MSC-let-7a on
PAH development.
Treatment with let-7a/MSCs attenuates pulmonary vascular
remodeling induced by MCT
Pulmonary vascular remodeling is the major characterization
of PAH with hyperplasia of PASMCs and deposition of
extracellular matrix (ECM) [1, 7]. To further clarify the
effect of MSC-let-7a on MCT-induced pulmonary vas-
cular remodeling, the expression of ECM protein fibro-
nectin (Fn) was determined. As shown in Fig. 3f, MCT
induced an approximately 4.57-fold increase in Fn
mRNA levels in the lung, which was notably attenuated
following MSC treatment. Moreover, a more obvious
decrease in Fn expression was seen in the MSC-let-7a
groups than that in the MSC groups. Specifically, the
elevated expression of α-SMA, a marker for SMCs that
is used to evaluate muscularization of pulmonary arteries,
was obviously restrained following injection with MSC-
let-7a (Fig. 3g). Importantly, the notable increase in wall
thickness of pulmonary arterioles was markedly restrained
when rats received MSC-let-7a administration (Fig. 3h). In
brief, these data suggested that MSC-let-7a might partici-
pate in MCT-induced pulmonary vascular remodeling.
Fig. 1 Characterization of MSCs. a Morphological characterization of MSCs at passage 3. b Flow cytometry analysis suggested the major
phenotype characteristics of MSCs (CD34−, Cd45−, CD44+, and CD90+). c To evaluate osteogenic ability of MSCs, cells were stained with 2%
Alizarin Red S. The Alizarin Red S-positive mineral deposits were observed in MSCs. d Cells were stained with 0.3% Oil Red O to assess their adipo-
genic ability. Analysis with a microscope confirmed the accumulation of lipids in MSCs. Magnification × 200
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Overexpression of let-7a in MSCs regulates hypoxia-
induced PASMC proliferation
Uncontrolled PASMC proliferation and resistance to apop-
tosis contribute to vascular remodeling and are widely ac-
cepted as the major pathological features of PAH [1, 7]. To
further elucidate the mechanism underlying the MSC-let-
7a-mediated protective effect against PAH, we analyzed the
MSC-let-7a function in PASMC proliferation. As expected,
exposure to hypoxia evoked PASMC proliferation by
approximately 1.89 times (Fig. 4a). However, co-culture
with MSCs significantly inhibited hypoxia-induced PASMC
proliferation, which was further augmented when PASMCs
were co-cultured with let-7a-overexpressed MSCs.
Additionally, hypoxia-triggered expression of known pro-
liferation markers Ki67 and PCNA were also dramatically
dampened after MSC-let-7a treatment (Fig. 4b and c).
Simultaneously, MSC-let-7a treatment mitigated cyclin
D1 levels in hypoxia-exposed PASMCs, concomitant with
the increase in the cell cycle inhibitor protein p21.
MSC-let-7a administration abrogates apoptosis resistance
of PASMC
As shown in Fig. 4d, MSC treatment deteriorated
PASMC cell apoptosis upon hypoxia. A higher apoptotic
rate of PASMCs was validated after co-culture with let-
7a-elevated MSCs and reached 31.2 ± 1.04% (Fig. 4e).
The increase in caspase 3 activity further identified the
enhanced impact of MSC-let-7a on PASMC apoptotic
response, in contrast to the MSC-treated group (Fig. 4f ).
Thus, MSC-let-7a could suppress PASMC growth by
dampening cell proliferation and antagonizing cell resist-
ance to apoptosis.
STAT3-BMPR2 signaling is involved in the growth
inhibition of PASMCs triggered with MSC-let-7a
The activation of the STAT3-BMPR2 pathway has been
documented in PAH animal models and can regulate
smooth muscle cell (SMC) growth [17]. To elucidate the
underlying mechanism involved in MSC-let-7a-mediated
inhibition of PASMC growth, the activation of STAT3
was determined. As shown in Fig. 5a, MSC-let-7a abro-
gated hypoxia-induced expression of p-STAT3 and
increased downstream BMPR2 expression, suggesting
that MSC-let-7a abolished the activation of the STAT3-
BMPR2 pathway. When stopping STAT3 signaling with
its inhibitor S31-201, the expression of BMPR2 was
enhanced (Fig. 5b). Furthermore, cessation of BMPR2
expression was increased in PASMCs following BMPR2
siRNA transfection (Fig. 5c). Notably, the suppressive
role of MSC-let-7a in SMC proliferation was also
restored when cells were pre-administered with BMPR2
siRNA (Fig. 5d). Moreover, the corresponding downregu-
lation in the expression of cell proliferation-related mole-
cules, including ki67, cyclin D1, and PCNA, was also
ameliorated (Fig. 5e). Furthermore, suppressing BMPR2
expression remarkably counteracted the pro-apoptotic
effect of MSC-let-7a on PASMCs (Fig. 5f). Taken together,
these data indicated that MSC-let-7a might regulate
PASMC growth majorly by the STAT3-BMPR2 pathway.
Fig. 2 Expression of let-7a in MSCs and PAH rats. Rats were injected
with MCT (60 mg/kg) for 2 weeks to induce the PAH model. Then,
PBS and MSCs were injected into rats with PAH. The expression of
let-7a was analyzed by quantitative RT-PCR (a). MSCs were exposed
to hypoxia (3% oxygen) or normoxia (control group) for 24 h. The
expression of let-7a was detected in control and hypoxia-treated
groups (b). To explore the effects of MSC-based therapy against
PAH, MSCs were exposed to Ad-let-7a or Ad-NC viruses and cultured
for 48 h. Then, quantitative RT-PCR was performed to detect let-7a
expression in MSCs (c). *p < 0.05
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Discussion
Recently, let-7a has generated broad interest as a promis-
ing therapeutic agent for several diseases associated with
proliferative and metabolic abnormalities, including can-
cer [24]. A previous study corroborated the downregula-
tion of let-7a in lung injury [25]. Interestingly, its decrease
has also been validated in PAH animal models and
patients [16, 19]. In this study, depression of let-7a was
observed in PAH rats. Moreover, MSC treatment en-
hanced let-7a expression in the lungs of PAH rats,
indicating a potential role of let-7a in MSC-mediated ther-
apy for PAH. Concomitantly, we also simulated the condi-
tion of PAH by hypoxia exposure in vitro and observed a
high expression of let-7a in hypoxia-treated MSCs,
Fig. 3 Effect of MSC-let-7a on the development of PAH. Rats were given PBS, MSCs, MSC-NC, or MSC-let-7a 2 weeks after intraperitoneal injection
with MCT. The blood samples were collected at 7, 14, and 21 days after injection. The expression of let-7a was analyzed by quantitative RT-PCR
(a) and, about 3 weeks later, the expression of let-7a was analyzed in lung tissues (b). The effect of MSC-let-7a on RVSP was analyzed by inserting
3-F Miller catheters into the right ventricle through the right jugular vein (c). Then, rats were euthanized and the hearts and lung tissues
were harvested. The ratios of RV/LV + S (d) and RV/BW (e) were determined to evaluate right ventricular hypertrophy. Following lysis with
RIPA buffer, the mRNA levels of Fn in lung tissues were detected by quantitative RT-PCR (f). The expression of α-SMA was analyzed by Western blotting
(g). Lung tissues were embedded in paraffin, and then were cut into serial 4-μm thick sections. Wall thickness was then evaluated by HE staining (h).
*p < 0.05. BW body weight, LV left ventricle, MCT monocrotaline, MSC mesenchymal stem cell, NC miR-control, PBS phosphate-buffered saline, RV right
ventricle, RVSP right ventricular systolic pressure, S septum, SMA smooth muscle actin
Cheng et al. Stem Cell Research & Therapy  (2017) 8:34 Page 7 of 11
suggesting that MSCs could induce the expression of let-
7a in the progression of PAH. Next, we explored the effect
of let-7a-modified MSCs on PAH. As expected, we suc-
cessfully detected the retention of MSCs in lung tissues.
Importantly, let-7a-MSC treatment obviously suppressed
RVSP and RVH, which is the final pathway leading to the
death of patients [1]. Furthermore, application of MSC-
let-7a also attenuated the wall thickness of pulmonary ar-
terioles and restrained the expression of ECM protein Fn
and α-SMA, indicating an inhibitory effect of MSC-let-7a
on vascular remodeling. Importantly, the MSCs modified
with let-7a exhibited more favorable effects in ameliorat-
ing MCT-induced PAH compared to the MSC-only
groups, indicating a promising potential therapeutic role
of MSC-let-7a in PAH.
Excessive proliferation and apoptosis resistance of
PASMCs are major pathological features of PAH and
rank as key events in the pathogenesis of PAH [7].
Furthermore, PASMC proliferation and migration also
facilitate the remodeling of the pulmonary artery, which
is a vital element of current PAH therapies [26]. Hypoxia
is widely accepted as a trigger of pulmonary vascular
remodeling and the subsequent pulmonary hypertension.
To elucidate the underlying mechanism involved in the
MSC-let-7a-mediated protective effect against PAH, the
proliferation and apoptosis of PASMCs were investi-
gated. Here, hypoxia exposure significantly induced
the proliferation of PASMCs, as supported by previ-
ous reports [27]. Nevertheless, this increase was miti-
gated when cells were incubated with MSC-let-7a.
Moreover, MSC-let-7a treatment remarkably attenu-
ated cell resistance to apoptosis. Therefore, these re-
sults confirmed that MSC-let-7a suppressed the
growth of PASMCs by suppressing cell proliferation
and cell resistance to apoptosis, which may ameliorate
the progression of PAH.
Fig. 4 MSC-let-7a administration dramatically inhibited PASMC proliferation and reduced its resistance to apoptosis. The rPASMCs were exposed
to hypoxia or normoxia for 24 h, followed by co-culture with modified MSCs (MSC-NC or MSC-let-7a) using the transwell system. Approximately
24 h after incubation, PASMCs were collected. Cell viability was analyzed by 3H-TdR (a). Cells were lysed with RIPA lysis buffer, followed by SDS–PAGE.
The specimens were then subjected to Western blotting analysis. The protein levels of Ki67, cyclin D1, p21, and PCNA were monitored by Gel DocTM
XR imaging system (b). The corresponding quantitative analysis was also carried out by Image J software (c). For cell apoptosis assay, about 10 μl
Annexin V-FITC and 5 μl PI was introduced. Flow cytometry was used to detect cell apoptosis (d, e). The caspase-3 activity was also determined using
a commercial kit to assess cell apoptosis (f). *p < 0.05. MSC mesenchymal stem cell, NC miR-control, PCNA proliferating cell nuclear antigen
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Signal transducers and activators of transcription 3
(STAT3) signaling exerts important roles in various
physiopathological processes, such as angiogenesis,
immune response, and cellular functions [28, 29]. Recent
research corroborated the abnormal activation of STAT3
signaling in PAH patients [17]. Moreover, the increase in
the pro-proliferative phenotype of PASMCs has been
shown to be associated with the activation of the
STAT3-BMPR2 pathway [17, 30–32]. Emerging studies
suggest that let-7a may restrain tumor cell proliferation
by blocking the STAT3 pathway [28, 33]. Accordingly, to
elucidate the mechanism involved in the inhibitory effect
of MSC-let-7a on PASMC growth, STAT3 signaling was
evaluated. Consistent with our previous hypothesis,
MSC-let-7a significantly antagonized p-STAT3 levels,
concomitant with the upregulation in its downstream
BMPR2. When blocking the STAT3 signaling with S31-
201, an antagonist of the STAT3 pathway, BMPR2
expression was increased. As a surface protein receptor
of BMPs, BMPR2 can be expressed on vascular SMCs
and identified as a well-established inhibitor of vascular
SMC proliferation, but it provokes cell death [31, 34].
Interestingly, suppression of PASMC proliferation and
enhancement of cell apoptosis triggered by MSC-let-7a
were obviously abated when silencing BMPR2 expres-
sion. Therefore, these data suggest that STAT3-BMPR2
signaling might account for MSC-let-7a-regulated
PASMC survival. However, blocking BMPR2 levels could
not absolutely abolish the effect of MSC-let-7a on
PASMC growth. Whether other molecules or pathways
Fig. 5 The STAT3-BMPR2 signaling was responsible for MSC-let-7a-regulated growth inhibition of PASMCs. After co-culture with MSCs modified
with let-7a or NC, the expression levels of STAT3, p-STAT3, and downstream BMPR2 were determined in PASMCs upon hypoxia by Western blotting.
Cells cultured under normoxia were defined as the control group (a). Following treatment with the STAT3 inhibitor S31-201 (15 μM), the protein levels
of BMPR2 in PASMCs were analyzed (b). Following preconditioning with BMPR2 siRNA for 24 h, the protein level of BMPR2 was determined by Western
blotting (c). PASMCs were treated with BMPR2 siRNA and co-cultured with or without MSC-let-7a. Cell proliferation (d) and proliferation-related gene
expression (including Ki67, cyclin D1, and PCNA) (e) were then determined. (f) Cell apoptosis was assessed by flow cytometry. *p < 0.05. BMPR2 bone
morphogenetic protein receptor 2, MSC mesenchymal stem cell, NC miR-control, PCNA proliferating cell nuclear antigen, siRNA small interfering RNA,
STAT3 signal transducers and activators of transcription 3
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are involved in this process will be explored in our
future research.
Conclusions
This study indicated that MSC-let-7a could ameliorate
the development of MCT-induced PAH by suppressing
the growth of PASMCs. Furthermore, the STAT3-
BMPR2 pathway was involved in MSC-let-7a-mediated
PASMC proliferation. As a whole, our research may
illustrate the protective role of MSC-let-7a in the pro-
gression of PAH. Therefore, this study provides the
groundwork for the further study of MSC-let-7a as a
therapeutic strategy against PAH. Thus, it may provide a
promising therapeutic approach for PAH. However, fur-
ther studies will explore the above mechanism in vivo.
This study only clarifies the effect of MSC-let-7a on
PAH in an animal model. There is still a long way to go
to investigate the application of MSC-let-7a in human
therapy, which will be the focus of our future research.
Futhermore, recent research has also corroborated the
critical implication of lipids, especially the oxidized
lipids, in the pathophysiological hallmarks of PAH, such
as SMC proliferation [35]. Interestingly, a previous study
also corroborated the protective effect of let-7a on oxi-
dized low-density lipoprotein-induced endothelial cell
injury [36]. Whether MSC-let-7a can attenuate the
development of PAH by regulating lipid metabolism will
provide a new direction for further research and will be
explored in our future research.
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